Pfizer shares surge nearly 4% on vaccine report
Pfizer and BioNTech said they have concluded phase 3 study.
Shares of Pfizer Ltd rose nearly 4% in early trade on Thursday after Pfizer Inc announced that the COVID-19 vaccine developed in partnership with BioNTech was found 95 per cent effective in the final analysis of the Phase 3 trial.
The stock surged by 3.83% to ₹ 5,098 on the BSE.
Similarly, on NSE, shares of Pfizer Ltd rose by 3.85% to ₹ 5,096.20.
Global drugmakers Pfizer and BioNTech said on Wednesday that their COVID-19 vaccine was found 95% effective in the final analysis of the Phase 3 trial, including in people aged over 65 years, paving the way for the companies to apply for emergency authorisation from US regulators within days.
Further, Pfizer and BioNTech said they have concluded phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy endpoints.
Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.
Mozambique Open to Support in Fighting Islamists, Lusa Says
Mozambique is ready to receive any support in its fight against Islamists in the northern natural-gas-rich Cabo Delgado province, Portuguese news agency Lusa reported, citing President Filipe Nyusi.
The government is working with its counterparts in Europe, the U.S., Asia and Africa to counter terrorism, the news agency cited Nyusi as saying, without providing further details.
More than 2,300 people have died in the violence that began three years ago, including reports of mass beheadings earlier this month, according to the Armed Conflict Location & Event Data Project, which tracks the fighting.
The war has already displaced more than 500,000 people in the province where Total SE plans to spend $20 billion on a natural-gas export project, privately owned Mozambican newspaper O Pais reported Thursday, citing Prime Minister Carlos Agostinho do Rosário. That’s more than a fifth of Cabo Delgado’s population.
Biovac, Sanofi Pasteur to Make Pediatric Vaccine in South Africa
Biovac, South Africa’s state vaccine company, will manufacture the Hexaxim vaccine under license from Sanofi Pasteur, marking the first manufacture of vaccines in the country since the mid 1990s.
The vaccine protects against six common diseases affecting infants, the companies said in a statement on Thursday.
Lagarde Pledges Forceful ECB Stimulus Response in December
European Central Bank President Christine Lagarde promised a forceful monetary stimulus package for December and urged governments to make pandemic-relief available “without delay.”
Speaking during a European Parliament committee hearing, Lagarde said European leaders should make adopting joint fiscal support a priority as the euro-area economy is expected to be severely affected by the fallout from the rapid increase in infections and restrictions.
The ECB “responded promptly and forcefully to the first wave that hit the euro area economies,” Lagarde said. “We will address the current phase of the crisis with the same approach and determination.”
— With assistance by Carolynn Look, Jeannette Neumann, and Alexander Weber
Netease Inc. Q3 adjusted earnings of RMB5.35 per share
Netease Inc. (NTES) released earnings for third quarter that fell from last year.
The company’s earnings totaled RMB2.79 billion, or RMB0.87 per share. This compares with RMB4.16 billion, or RMB1.27 per share, in last year’s third quarter.
Excluding items, Netease Inc. reported adjusted earnings of RMB3.67 billion or RMB5.35 per share for the period.
The company’s revenue for the quarter rose 27.5% to RMB18.66 billion from RMB14.64 billion last year.
Netease Inc. earnings at a glance:
-Earnings (Q3): RMB3.67 Bln. vs. RMB4.73 Bln. last year.
-EPS (Q3): RMB5.35 vs. RMB7.26 last year.
-Revenue (Q3): RMB18.66 Bln vs. RMB14.64 Bln last year.
Syncona Swings To Profit In H1
Healthcare company Syncona Ltd. (SYNC.L) reported profit after tax of £119.9 million or 17.86p per share compared to a loss of £105.2 million or 15.67p per share last year.
Total investment income was £12.9 million compared to £26.1 million reported in the prior year period.
Martin Murphy, Chief Executive Officer Syncona Investment Management Ltd., said, “Syncona has delivered a robust performance, underpinned by a strong balance sheet and disciplined capital allocation. We have recently founded and invested in two exciting new companies with ambitions to deliver transformational treatments to patients. We also made an investment in an exceptional emerging cell therapy company and continued to invest and support our portfolio companies as they achieved key clinical and financial milestones, despite the unprecedented backdrop of the COVID-19 pandemic.”
Grainger Plc FY Adj. Pretax Profit Slightly Declines – Quick Facts
Grainger plc (GRI.L) reported profit before tax of 110.8 million pounds for the year ended 30 September 2020 compared to 131.3 million pounds, previous year. Earnings per share was 14.2 pence compared to 19.8 pence. Adjusted pretax profit declined to 81.8 million pounds from 82.5 million pounds. Adjusted earnings per share was 10.2 pence compared to 11.5 pence.
Fiscal year Group revenue declined to 214.0 million pounds from 222.8 million pounds, last year. Net rental income increased by 16% to 73.6 million pounds. Like-for-like rental growth remained at 3.0%, for the period.
The Group proposed final dividend of 3.64 pence per share. This equates to a total dividend for the year of 5.47 pence per share, a 5% increase on a per share basis compared to the prior year.